APL-2
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia
Conditions
Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Trial Timeline
Aug 31, 2017 → Sep 12, 2022
NCT ID
NCT03226678About APL-2
APL-2 is a phase 2 stage product being developed by Apellis Pharmaceuticals for Warm Autoimmune Hemolytic Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03226678. Target conditions include Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04085601 | Phase 3 | Completed |
| NCT03453619 | Phase 2 | Completed |
| NCT03226678 | Phase 2 | Completed |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |